Will Battershill and Hollie Wheat from Delta Hat discuss key insights into HTA decision-making from ISPOR Europe. Will explores the hot topic of incorporating patient and carer perspectives into decision-making, whilst Hollie dives into the use of surrogate endpoint evaluation in HTA decision-making.
Discover our tailored health economics training for Pharma and Medtech teams. Delivered by experts, it combines practical insights with real-world experience.
Challenges for orphan medicines entering the European market – Part 3: Economic evidence development
Evelyne Priestman who recently joned our Health Economics Team, shares what inspired her to join Mtech Access and her experiences since joining the team
Calum Jones (Associate Director – Health Economics) shares his experience speaking at the 2024 HTAi Conference. Calum participated in the panel discussion: ‘Surrogate Endpoints in Health Technology Assessment (HTA): From Trials to Economic Evaluations’.
Hannah Palin (Director – Market Access) and Calum Jones (Associate Director – Health Economics) explore the landscape for economic evaluation in the US and highlight important considerations for companies seeking to infiltrate this key market.
We delve into ICER’s influence on drug pricing and access in the US. We also explore the importance of maximising engagement with ICER for favourable pricing and access outcomes.
Hayley Shoel shares her experience of joining Mtech Access’ specialist medical writing team. Explore the different types of projects she’s working on. Discover what you could expect if you joined us at Mtech Access.